JP2004517049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517049A5 JP2004517049A5 JP2002525102A JP2002525102A JP2004517049A5 JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5 JP 2002525102 A JP2002525102 A JP 2002525102A JP 2002525102 A JP2002525102 A JP 2002525102A JP 2004517049 A5 JP2004517049 A5 JP 2004517049A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- salt
- functional derivative
- physiologically functional
- ylidene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- HCKUFQKWZDUIHQ-UHFFFAOYSA-N 1-[4-[2-(4-chloro-5-hydroxy-2-oxo-6-propan-2-ylindol-3-yl)hydrazinyl]phenyl]-n-methylmethanesulfonamide Chemical compound C1=CC(CS(=O)(=O)NC)=CC=C1N\N=C/1C2=C(Cl)C(O)=C(C(C)C)C=C2NC\1=O HCKUFQKWZDUIHQ-UHFFFAOYSA-N 0.000 claims 1
- -1 5-Methyl-1,3,4-thiadiazol-2-yl Chemical group 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 101150111783 NTRK1 gene Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- UGKCASUMDGHTLI-UVTDQMKNSA-N n-[4-[[(z)-(2-oxo-1h-indol-3-ylidene)methyl]amino]phenyl]methanesulfonamide Chemical compound C1=CC(NS(=O)(=O)C)=CC=C1N\C=C/1C2=CC=CC=C2NC\1=O UGKCASUMDGHTLI-UVTDQMKNSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23005000P | 2000-09-01 | 2000-09-01 | |
| PCT/US2001/026423 WO2002020479A1 (en) | 2000-09-01 | 2001-08-23 | Substituted oxindole derivatives as tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517049A JP2004517049A (ja) | 2004-06-10 |
| JP2004517049A5 true JP2004517049A5 (https=) | 2005-04-07 |
Family
ID=22863755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002525102A Pending JP2004517049A (ja) | 2000-09-01 | 2001-08-23 | チロシンキナーゼ阻害剤としての置換オキシインドール誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7071217B2 (https=) |
| EP (1) | EP1339680A1 (https=) |
| JP (1) | JP2004517049A (https=) |
| AU (1) | AU2001288374A1 (https=) |
| WO (1) | WO2002020479A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001288374A1 (en) * | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| AU2002341881B2 (en) * | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| WO2005000194A2 (en) | 2002-10-08 | 2005-01-06 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| DK2270048T3 (en) | 2002-12-24 | 2016-01-18 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods for their use |
| BRPI0407375A (pt) | 2003-02-19 | 2006-02-07 | Rinat Neuroscience Corp | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos |
| MXPA06007017A (es) | 2003-12-18 | 2006-08-31 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidina como agentes antiproliferativos. |
| EP3372614B1 (en) | 2004-04-07 | 2022-06-08 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
| WO2005118551A2 (en) * | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
| CA2583764C (en) * | 2004-10-25 | 2009-06-09 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| BRPI0606793A8 (pt) | 2005-02-04 | 2018-03-13 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica |
| SI1853588T1 (sl) | 2005-02-16 | 2008-10-31 | Astrazeneca Ab | Kemične spojine |
| US20080287437A1 (en) | 2005-05-16 | 2008-11-20 | Astrazeneca Ab | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| US7879318B2 (en) * | 2006-01-23 | 2011-02-01 | Mcw Research Foundation, Inc. | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand |
| JP5182088B2 (ja) | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| JP2009542778A (ja) | 2006-07-13 | 2009-12-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｍｔｋｉキナゾリン誘導体 |
| TW200826937A (en) * | 2006-11-01 | 2008-07-01 | Astrazeneca Ab | New use |
| TW200823196A (en) * | 2006-11-01 | 2008-06-01 | Astrazeneca Ab | New use |
| CA2687909C (en) | 2007-06-21 | 2015-09-15 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
| AU2008281849B2 (en) | 2007-07-27 | 2013-11-28 | Janssen Pharmaceutica Nv | Pyrrolopyrimidines |
| EP2206707B1 (en) | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| WO2009088054A1 (ja) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | 精巣の疼痛又は不快感行動及び頻尿併発モデル動物 |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| EP4514998A1 (en) | 2022-04-27 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score |
| CN117624014A (zh) * | 2022-11-02 | 2024-03-01 | 徐诺药业(南京)有限公司 | 3-(吲哚氨基)亚甲基吲哚啉类衍生物及其制备方法和应用 |
| EP4680973A1 (en) | 2023-03-17 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for osteoarthritis (oa) |
| WO2026054762A1 (en) | 2024-09-05 | 2026-03-12 | Regeneron Pharmaceuticals, Inc. | Proteomic risk score for adjudicated arthropathy (aa) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6269086B1 (en) | 1998-02-27 | 2001-07-31 | Legerity, Inc. | Arrangement and method for selectable time/frequency division multiplex communication |
| DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| US6492398B1 (en) | 1999-03-04 | 2002-12-10 | Smithkline Beechman Corporation | Thiazoloindolinone compounds |
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6498176B1 (en) | 1999-03-04 | 2002-12-24 | Smithklinebeecham Corporation | 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| US6620818B1 (en) | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
| AU2001288374A1 (en) * | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| EP1430053B1 (en) | 2001-09-27 | 2006-10-25 | SmithKline Beecham Corporation | AZAOXOINDOLE DERIVATIVES AS Trk PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND CHRONIC PAIN |
-
2001
- 2001-08-23 AU AU2001288374A patent/AU2001288374A1/en not_active Abandoned
- 2001-08-23 WO PCT/US2001/026423 patent/WO2002020479A1/en not_active Ceased
- 2001-08-23 EP EP01968099A patent/EP1339680A1/en not_active Withdrawn
- 2001-08-23 US US10/362,743 patent/US7071217B2/en not_active Expired - Fee Related
- 2001-08-23 JP JP2002525102A patent/JP2004517049A/ja active Pending
-
2005
- 2005-06-09 US US11/148,635 patent/US7338966B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517049A5 (https=) | ||
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2004517087A5 (https=) | ||
| JP2005508337A5 (https=) | ||
| RU2004117887A (ru) | Ариланилиновые агонисты бета2 адренергических рецепторов | |
| RU2008112221A (ru) | Соединения ряда изоиндолимидов, их композиции и способы применения | |
| JP2005523922A5 (https=) | ||
| JP2014502979A5 (https=) | ||
| AU2011227398A1 (en) | Modulators of Hec1 activity and methods therefor | |
| JP2010501478A5 (https=) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2020512337A5 (https=) | ||
| JP2022511477A5 (https=) | ||
| TWI731854B (zh) | Ｃ型肝炎病毒聚合酶之抑制劑 | |
| JP2008534453A5 (https=) | ||
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| JP2022533958A5 (https=) | ||
| EP3286179A1 (en) | Compositions and methods for inhibiting kinases | |
| JP2007501284A5 (https=) | ||
| JP2006516626A5 (https=) | ||
| JP2009501745A5 (https=) | ||
| JP2022527618A5 (https=) | ||
| RU2007120710A (ru) | Способ лечения рака и/или лейкоза и применяемая в нем фармацевтическая композиция | |
| RU2004104329A (ru) | Ацилсемикарбазиды как ингибиторы циклинзависимой киназы, полезные в качестве противораковых и противопролиферативных агентов | |
| JP2006513222A5 (https=) |